Namenda XR (Memantine HCl) Patent Expiration, LOE Window & CMS Spending

Namenda XR (Memantine HCl) by AbbVie: FDA Orange Book LOE 2029-09-24, 8 AB generics, $719K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN022525 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2029-09-24
Orange Book Patents (*PED Extensions)2 patents (1 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$719K
2024 Medicare Part D Spend$699K
2024 Medicaid Spend$20K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.